The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)

Clinical research

Differentiated analysis of an everolimus-eluting stent and a paclitaxel-eluting stent among higher risk subgroups for restenosis: results from the SPIRIT II trial

EuroIntervention 2008;3:566-573 - DOI10.4244/EIJV3I5A102.

1. Herz-Kreislauf-Zentrum Segeberger Kliniken GmbH (Academic Teaching Hospital of the University of Kiel), Bad Segeberg, Germany; 2. Hopital Cantonal Universitaire, Geneva, Switzerland; 3. Rigshospitalet, Copenhagen, Denmark; 4. Hospital Clinico San Carlo

Aims: Restenosis is higher among certain subpopulations when subjected to percutaneous coronary interventions even when using drug-eluting stents. The randomised SPIRIT II trial demonstrate

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

Read next article
First clinical comparison of Nobori –Biolimus A9 eluting stents with Cypher– Sirolimus eluting stents: NOBORI CORE nine months angiographic and one year clinical outcomes